Coala Life receives FDA 510k clearance for remote lung auscultation and enhanced ECG algorithm.
Coala raises SEK 150 million in a fully guaranteed rights issue
Health economic analysis by Swedish Dental and Pharmaceutical Benefits Agency shows cost-effectiveness of using Coala in primary care
Coala discloses a US business update including 10 new RPM agreements signed until end of first quarter
The TITAN-DM study where Coala is used long-term on people with diabetes is fully recruited with 600 participants
Coala goes public on Nasdaq First North Stockholm (Nasdaq: COALA.ST)
Coala announces reverse IPO into Nasdaq Stockholm via acquisition by RNB
Partnership with Region Gävleborg and researchers of Karolinska Institute to run a 3 month study on patients with diabetes using the Coala platform
Coala awarded the 2021 Frost & Sullivan New Product Innovation Award – Cardiac Monitoring.
Protocol for using Coala on long-term management of patients with palpitation issues and related symptoms. Read here.
Launch of new unique features including Coala Automated Monitoring Report and enhanced sound filters for remote auscultation.
Launch of managed RPM by Coala to help providers run seamless and compliant RPM programs.
TGA approval in Australia
RedHeart Study published proving that the Coala helps reduce symptoms of palpitations and increases quality of life in over 800 women
Coala introduced for post-Ablation monitoring at one of the leading US healthcare system
Launch of service to help enhance and leverage cardiac rehab programs.
Launch of the Coala Connect Rx direct-to-patient telecardiology service in the US
Coala introduced as screening tool of athletic students returning back from Covid-19 at one of US largest high schools
First patient-reported feasibility study of Coala published in BMJ, with excellent patient feedback
TEASE-study is published in BMJ validating the use of Coala for post-cryptogenic stroke monitoring
Coala Life and MyCardiologist to roll-out the largest Real-Time Cardiac Monitoring program in Florida
Coala Life rolls out in major cardiology clinics in Texas and California
Expanded FDA indication to allow for automatic detection of 9 of the most common arrhythmias during COVID-19 emergency
Expanded FDA indication to allow for lung sound monitoring during COVID-19 emergency
Perry Virtual first major rural health program in US to use Coala for remote monitoring
Launch of home enrollment service in the US to help reduce risk of COVID-exposure
Scientific data presented at the AHA EPI 2020 meeting in Phoenix confirmed again the superior accuracy of the Coala Heart Monitor
Coala Life pioneers new post-procedure protocol in partnership with Dr Reginald Abraham, a leading US cardiothoracic surgeon based in CA, USA
Coala is awarded with the Cardiology 2.0 Impact Award for 2020
Coala Life enters technology partnership with multi-billion medical device company Asahi Kasei in Japan to expand into Heart Failure market
Coala Life partners with California-based High Desert Heart Institute as the first major healthcare provider contract for Coala Life in the US
Aleris, one of the largest healthcare providers in Northern Europe, completes a successful evaluation and clinical implementation of the Coala Heart Monitor at the Sabbatsberg Hospital. Read the report here.
First patients diagnosed and treated for Atrial Fibrillation in the US thanks to Coala
Coala's US advisory board assembled with leading industry professionals
Coala Life is listed by the Wired as one of the 100 hottest start-ups in Europe.
Clinical performance results are presented on the Digital Health stage at the world's largest cardiology meeting - European Society of Cardiology (ESC) - including results from the Red Heart Study.
Coala Life expands into the US market with office in Irvine, CA, and sales team spread across USA.
Coala partners with Luscii and enters the Dutch market
Coala Life Inc is established on the US market and first team on board. Coala enters the German market in partnership with Arteriomed GmbH.
Microsofts CEO Satya Nadella highlights Coala Life as major game changer in healthcare part of his keynote presentation in Stockholm
Coala Life elected by Valuer.ai as the leading MedTech startup in Sweden.
Coala Life elected by Norrsken as one of the #theimpact100 companies, with goal and passion to solve global challenges.
Coala Life secures A-series funding of total USD 11 million for expansion into the US market.
New research presented confirming the leading clinical accuracy of the Coala Heart Monitor, see here
Coala Life signs commercialisation agreement with Apotek Hjärtat, the largest Pharmacy retailer in Sweden
Coala Heart Monitor is cleared by the FDA, read pressrelease here.
Coala Life is recognized as one of 100 top Global leaders in Digital Health by The Journal of mHealth
Coala introduces new, unique algorithms with advanced P-wave detection and compatibility with Apple Health Records. Read more here.
Performance assessment study presented at American Heart Association 2018, and published in Circulation.
Coala Life elected by research firm PUBLIC as one of the leaders of the digital transformation of public healthcare.
Coala presents at the Health 2.0 conference in Santa Clara, US.
Coala named "Cool Vendor 2018" by Gartner.
Coala attends and presents at the Digital Health Pavilion of ESC 2018, the largest cardiovascular meeting in the world.
Coala Life is recognized by Red Herring as one of Europe's Top-100 start-ups.
Coala Life wins the People's Choice Award of the prestigious 2018 Grand Award of Design.
Publishing of clinical performance data at the 2018 Spring Cardiovascular Spring meeting in Stockholm.
Results from joint-project with Praktikertjänst (the largest private healthcare provider in Sweden) is presented proving a reduction in specialist referrals with almost 40%, with reduced costs and satisfied users as results.
The University Hospital in Lund starts using the Coala Pro for smart and Digital cardiac assessments.
Coala Life wins the Startup World Cup finals in Sweden and heading for the global grand finale in Silicon Valley.
Coala Life signs deal with global life science company Bayer. Read article here.
Coala Life raises additional growth capital and extends the Board.
Coala receives a major grant from the Swedish Governmental agency for Innovation Systems (Vinnova) to further develop Artificial Intelligence to enable early prediction of heart disease.
Coala Life is awarded the prestigious Rising Star Award 2017 at the Swedish American Life Science Summit.
Coala is used in unique new clinical study on stroke patients.
Launch of the Coala Pro, a unique digital solution for caregivers and professional users to enable efficient, high performance yet simple arrhythmia assessments as well as diagnosing and managing patients with AFIB.
Coala Life wins the prestigious eHealthAward 2017, handed over by the Swedish Minister of Health.
The Coala is launched in Sweden and sold online and in retail by LloydsPharmacy in Sweden.
Coala Life is a proud winner and part of "Sweden’s 33 hottest tech companies list 2017".
Coala is CE-approved and Coala Life is ISO 13485 certified.
Coala Life AB is founded after the fourth generation technology platform and analysis algorithms are successfully verified.
Coala research is initiated by Swedish entrepreneurs and physicians with the goal of developing wireless systems for digital monitoring and diagnosing of the heart.